Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2025 | Intronic DNA variants in EZH2 and GATA2 may predict TFR in CML

Shaun Patterson • 7 Dec 2025
ASH 2025
Chronic Myeloid Leukemia Leukemia
DESTINY

Shaun Patterson, PhD, University of Glasgow, Glasgow, UK, shares insights into the DESTINY trial (NCT01804985), which investigated the discontinuation of TKIs in patients with chronic myeloid leukemia (CML). He states that intronic DNA variants, including EZH2 and GATA2, may predict treatment-free remission (TFR), and further suggests that these findings could be validated in a larger prospective clinical trial to potentially improve patient stratification and quality of life. This interview took place at the 67th ASH Annual Meeting and Exposition, held in Orlando, FL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Related Videos

CARDINAL: Phase I study of TERN-701, an allosteric BCR-ABL1 inhibitor, in previously treated CML
2:19
CARDINAL: Phase I study of TERN-701, an allosteric BCR-ABL1 inhibitor, in previously treated CML
Shaun Patterson • 24 Nov 2025
VICEROY study: azacitidine, venetoclax, and gilteritinib in FLT3-mutated AML
3:31
VICEROY study: azacitidine, venetoclax, and gilteritinib in FLT3-mutated AML
Shaun Patterson • 8 Dec 2025
Concurrent loss of TP53 and CDKN2A with tetraploidy predicts RT and poor prognosis in CLL
2:18
Concurrent loss of TP53 and CDKN2A with tetraploidy predicts RT and poor prognosis in CLL
Shaun Patterson • 8 Dec 2025
The risk of Richter's transformation in the era of targeted therapy
3:31
The risk of Richter's transformation in the era of targeted therapy
Shaun Patterson • 7 Dec 2025
The content of VJHemOnc is intended for healthcare professionals